Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3WNo differences in efficacy were observed across different CLDN18.2 expression levels, with favorable overall safetyData anchor combination clinical strategy in first line (1L) gastric cancer, a $2B potential market1Confirming Q1 2026 plans to report topline Phase 1b dose ...

America’s Diner continues its long-standing tradition of saying 'thank you' to all active and retired military personnel Denny's Veterans Day 2025 Denny’s Honors Veterans with Free Original Grand Slam® for Veterans Day Spartanburg, S.C., Oct. 22, 2025 (GLOBE NEWSWIRE) -- This Veterans Day, Denny’s invites active and retired military personnel to America’s Diner to enjoy a FREE Original Grand Slam® from 5 a.m. (store open) to noon local time at participating locations nationwide*. The iconic, guest-favori ...

Q3 2025 REVENUES In challenging market conditions and an uncertain geopolitical environment, Synergie recorded Revenues of €825.0 million in the third quarter of 2025, an increase of +1.8 % year-on-year. In € millionQ3 2025Q3 2024Variation9M 20259M 2024VariationInternational505.1497.4+1.5%<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ...

Core Insights - Voltalia reported a strong growth in Q3 2025, with turnover increasing by 31% to 164.7 million euros, primarily driven by a significant rise in third-party services [2][5][7] - The company's operational and financial objectives for 2025 remain aligned with forecasts, with the SPRING transformation plan entering its implementation phase [2][21][23] Financial Performance - Q3 2025 turnover reached 164.7 million euros, up 31% compared to Q3 2024, with a 33% increase at constant exchange rates [5][7] - Energy Sales turnover decreased by 13% to 85.2 million euros, impacted by unfavorable exchange rates and curtailment in Brazil [4][11] - Services to third parties saw a remarkable growth of 2.8 times, reaching 79.5 million euros, driven by construction activities in Ireland, Spain, and the UK [12][13][14] Production and Capacity - Energy production in Q3 2025 was 1.3 terawatt-hours, a 6% increase from Q3 2024, attributed to improved resource levels and increased operational capacity [9][33] - Total energy production for the first nine months of 2025 reached 3.6 terawatt-hours, up 11%, despite a curtailment of 651 gigawatt-hours in Brazil [8][11] - The operational capacity as of September 30, 2025, was 3.3 gigawatts, with a 7% increase in capacity under construction [4][28] Strategic Developments - The company is actively pursuing disposals of development activities in Hungary, Slovakia, and Mexico, expected to be completed by Q2 2026 [23] - Voltalia has initiated the sale of its Spanish development platform, aiming for completion by summer 2026 [23] - The SPRING transformation plan includes the subsidiarization of construction and maintenance activities, projected to be completed in Q1 2026 [23] Market Position and Future Outlook - Voltalia's services segment accounted for 44% of total turnover in the first nine months of 2025, highlighting its strong position in the renewable energy market [6] - The company aims to achieve an EBITDA of 200 to 220 million euros for 2025, with expectations of a higher net loss in the second half of the year due to restructuring costs [21][24]

Core Insights - Revolution Medicines, Inc. announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) [1][2] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [9] - The company's R&D pipeline includes RAS(ON) inhibitors designed to suppress various oncogenic variants of RAS proteins, including daraxonrasib, elironrasib, and zoldonrasib [9] Clinical Data Highlights - As of August 4, 2025, elironrasib was administered to 24 heavily pretreated patients with KRAS G12C NSCLC, showing a confirmed objective response rate of 42% and a disease control rate of 79% [2][4] - The median duration of response was 11.2 months, with a median progression-free survival of 6.2 months, and a 12-month overall survival rate of 62% [2][4] Treatment Context - NSCLC accounts for 80%-85% of all lung cancers, with KRAS mutations present in nearly 30% of NSCLC cases, making KRAS G12C the most common variant [5][7] - Elironrasib has received Breakthrough Therapy Designation for treating adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior chemotherapy and immunotherapy [4] Upcoming Presentations - The AACR-NCI-EORTC Symposium will feature oral presentations highlighting the clinical activity of elironrasib and encouraging preclinical data supporting the RAS(ON) inhibitor platform [2][6]

Accessibility StatementSkip Navigation Faster Fixes, Fewer OutagesA new electric substation is planned to be up and running by December 2026. It will be connected to the existing Sydney Substation by two new half-mile power lines. These additions will bring more electricity to the area, making the system more flexible if a customer's main power line is taken out of service and will help crews restore power more quickly during outages. Construction recently kicked off on new substation and backup power lines ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased WPP plc ("WPP†or the "Company†) (NYSE: WPP) common stock between February 27, 2025 and July 8, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WPP PLC (WPP), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWS. ...

Q3 2025 REVENUES In challenging market conditions and an uncertain geopolitical environment, Synergie recorded Revenues of €825.0 million in the third quarter of 2025, an increase of +1.8 % year-on-year. In € millionQ3 2025Q3 2024Variation9M 20259M 2024VariationInternational505.1497.4+1.5%<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ...

PRESS RELEASE - REGULATED INFORMATION HYBRID SOFTWARE GROUP REPORTS Q3 REVENUE UP 16% AND OPERATING PROFIT UP 200% FROM LAST YEAR Cambridge (UK) 22 October 2025 (18.00 CEST) – Hybrid Software Group PLC (Euronext: HYSG) provides a trading update for the nine months ended 30 September 2025. This information is unaudited. For the quarter ended 30 September 2025: Revenue for the period was €13.42 million (2024: €11.57 million)EBITDA for the period was €3.52 million, or 26% of revenue (2024: €2.01 million, 17% o ...

Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeu ...